Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD)

Glaxo will be promoting Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD).

It's the first drug approved for this use.

Up to 10% of people at northern latitudes get depressed in the fall and winter. It's thought that shorter days trigger changes in melatonin, serotonin, and other neurotransmitters.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote